secwatch.observer — SEC 8-K summary
======================================

Issuer:     Mereo BioPharma Group plc (MREO)
CIK:        0001719714
Form:       8-K
Filed at:   2026-03-19T23:59:59+00:00
Accession:  0001193125-26-115211
Event type: earnings
Sentiment:  negative
Materiality: 0.65
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Mereo BioPharma FY2025 net loss $41.9M; setrusumab Phase 3 studies miss primary endpoints, show BMD gains
--------------------------------------------------------------------------------

- Cash $41.0M as of Dec 31, 2025; expected runway into mid-2027 (from $69.8M end 2024).
- Setrusumab Phase 3 Orbit & Cosmic missed primary endpoint (annualized clinical fracture rate) but achieved high statistical significance on BMD improvement.
- Setrusumab showed vertebral fracture reductions and statistically significant PRO improvements in pain/daily activity in pediatric patients.
- Alvelestat site feasibility for Phase 3 in AATD-LD complete; partnering discussions ongoing; Phase 2b in bronchiectasis designed.
- Vantictumab outlicensed to āshibio; Phase 2 in osteopetrosis planned H2 2026.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1719714/000119312526115211/0001193125-26-115211-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1719714/000119312526115211/mreo-20260319.htm
  HTML page:      https://secwatch.observer/filing/0001193125-26-115211

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer